Copyright
©The Author(s) 2015.
World J Nephrol. Jul 6, 2015; 4(3): 330-344
Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.330
Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.330
Figure 7 The dose after dialysis (DHD) replaces both the dose adjusted for kidney failure (Dfail), and the supplementary dose (Dsuppl) that compensates for the fraction (FR) removed during hemodialysis (HD).
- Citation: Keller F, Schröppel B, Ludwig U. Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. World J Nephrol 2015; 4(3): 330-344
- URL: https://www.wjgnet.com/2220-6124/full/v4/i3/330.htm
- DOI: https://dx.doi.org/10.5527/wjn.v4.i3.330